BERLIN, May 7 (Reuters) - The main challenge to raising
production of COVID-19 vaccines is how to quickly and
effectively transfer technology, Germany's health minister said
Friday, reiterating Berlin's opposition to a U.S. proposal to
waive patent protection.
"The main issue is not patent protection but production
capacity," Jens Spahn told a news conference on Friday.
In a jab at the Biden administration, Spahn also said: "I
would be delighted if the United States shows the same
willingness to export vaccines that we in Germany do."
(Reporting by Douglas Busvine and Paul Carrel, editing by Riham
Alkousaa)